Stamellou E, Seikrit C, Tang S, Boor P, Tesar V, Floege J
Nat Rev Dis Primers. 2023; 9(1):67.
PMID: 38036542
DOI: 10.1038/s41572-023-00476-9.
Baba T, Ishizaki T
Drugs. 2017; 43(4):464-489.
PMID: 28421556
DOI: 10.2165/00003495-199243040-00004.
Grossman A, Grossman E
Cardiovasc Diabetol. 2017; 16(1):3.
PMID: 28056987
PMC: 5217560.
DOI: 10.1186/s12933-016-0485-3.
Teo B, Chua H, Wong W, Haroon S, Subramanian S, Loh P
Singapore Med J. 2016; 57(5):267-73.
PMID: 27212015
PMC: 4876417.
DOI: 10.11622/smedj.2016089.
Chu P, Campbell M, Miller S, Hill K
World J Cardiol. 2014; 6(5):234-44.
PMID: 24944754
PMC: 4062129.
DOI: 10.4330/wjc.v6.i5.234.
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
Toto R, Tian M, Fakouhi K, Champion A, Bacher P
J Clin Hypertens (Greenwich). 2008; 10(10):761-9.
PMID: 19090877
PMC: 8672970.
DOI: 10.1111/j.1751-7176.2008.00016.x.
Hypertension management in patients with diabetic nephropathy.
McCall A
Curr Hypertens Rep. 2004; 6(4):272-9.
PMID: 15257861
DOI: 10.1007/s11906-004-0021-9.
Use of calcium antagonists in renal patients: therapeutic benefit or medical malpractice?.
Nigbor D, Lewis J
Curr Hypertens Rep. 2003; 5(5):430-6.
PMID: 12948437
DOI: 10.1007/s11906-003-0090-1.
The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.
Kalantarinia K, Siragy H
Curr Diab Rep. 2003; 2(5):423-30.
PMID: 12643168
DOI: 10.1007/s11892-002-0107-1.
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
Sica D, Bakris G
J Clin Hypertens (Greenwich). 2002; 4(1):52-7.
PMID: 11821641
PMC: 8099376.
DOI: 10.1111/j.1524-6175.2002.00749.x.
Renal protection and antihypertensive drugs: current status.
Salvetti A, Mattei P, Sudano I
Drugs. 1999; 57(5):665-93.
PMID: 10353294
DOI: 10.2165/00003495-199957050-00002.
Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
Baba T, Neugebauer S, Watanabe T
Drugs. 1997; 54(2):197-234.
PMID: 9257079
DOI: 10.2165/00003495-199754020-00002.
ACE inhibitors and proteinuria.
Gansevoort R, de Zeeuw D, de Jong P
Pharm World Sci. 1996; 18(6):204-10.
PMID: 9010883
DOI: 10.1007/BF00735961.
A comparative review of the adverse effects of calcium antagonists.
Dougall H, McLay J
Drug Saf. 1996; 15(2):91-106.
PMID: 8884161
DOI: 10.2165/00002018-199615020-00002.
Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life.
Cooper M, Vranes D, Rumble J
Drugs Aging. 1996; 8(1):38-46.
PMID: 8785467
DOI: 10.2165/00002512-199608010-00007.
The diabetic patient with hypertension.
Leese G, Savage M, Chattington P, Vora J
Postgrad Med J. 1996; 72(847):263-8.
PMID: 8761497
PMC: 2398457.
DOI: 10.1136/pgmj.72.847.263.
Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes.
Dawson K, McKenzie J, Ross S, Chiasson J, Hamet P
CMAJ. 1993; 149(6):821-6.
PMID: 8374845
PMC: 1485364.
Diltiazem. A review of its pharmacology and therapeutic use in older patients.
Markham A, Brogden R
Drugs Aging. 1993; 3(4):363-90.
PMID: 8369596
DOI: 10.2165/00002512-199303040-00007.
Do calcium channel blockers have renal protective effects?.
Reams G
Drugs Aging. 1994; 5(4):263-87.
PMID: 7827397
DOI: 10.2165/00002512-199405040-00004.
The kidney and arterial hypertension.
Ruilope L, Campo C, Lahera V
Drugs. 1993; 46 Suppl 2:108-12.
PMID: 7512463
DOI: 10.2165/00003495-199300462-00019.
